Neurosense Therapeutics Ltd. NRSN 深 沪
已收盘 05-15 16:00:00 美东时间
0.8266
-0.024
-2.86%
华盛通- 最 高0.8575
- 今 开0.8524
- 成交量 4.33万股
- 最 低 0.82
- 昨 收 0.8509
- 总市值 2984.01万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.63
- 委 比 -99.04%
- 总股本 3609.98万
- 历史最高 8.18
- 量 比 0.52
- 振 幅 4.41%
- 历史最低 0.40
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an update. On April 28, 202...
04-29 03:57
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeu...
04-29 02:30
NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that
04-06 21:21
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6...
04-06 21:20
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement NeuroSense received Nasdaq notices for failing to meet continued listing standards on minimum bid price, Nasdaq rule 5550(a)(2), plus market value of listed securities, Nasdaq rule 5550(b)(2). Non-compliance followed ordina
04-03 22:03
NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.35) by 25.71 percent.
03-31 21:28
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks NeuroSense rescheduled its pre-New Drug Submission meeting with Health Canada to May 2026 to include additional clinical, biomarker, and survival analyses for PrimeC. Clinical and biomarker results from NeuroS
03-24 21:03
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
03-10 18:40
NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the
02-18 22:14
